Zevra Q2 Revenue Surges 53% to $39.7M, Beats Consensus; Cash Pile Grows to $260M After Debt Payoff
ZVRA sits 47% above its 52-week low of $7.16.
Summary
Zevra's Q2 revenue of $39.7M beat estimates by 17%, fueled by MIPLYFFA. The company is debt-free with $260M in cash, but faces a European regulatory hurdle for arimoclomol.
Key Events · Earnings and Guidance · ZVRA
-
Q2 Revenue Beats Consensus
Revenue of $39.66M grew 53% YoY, exceeding the $33.88M consensus. MIPLYFFA contributed $30.2M and the global expanded access program added $9.0M.
-
Debt-Free Balance Sheet
The $63.1M term loan was fully repaid in March 2026. Cash, equivalents, and investments totaled $260.2M at quarter-end, providing a multi-year runway.
-
European Regulatory Setback
In July 2026, the CHMP adopted a negative opinion on the arimoclomol MAA. Zevra has requested a re-examination; a final decision is pending.
-
Celiprolol Phase 3 Enrollment Update
The DiSCOVER trial for Vascular Ehlers-Danlos syndrome has enrolled 66 participants as of June 30, 2026. A Type C meeting with the FDA was held in Q1 2026 to discuss potential acceleration.
Analysis · ZVRA · Life Sciences
Accelerating commercial traction for Zevra's rare-disease drugs marks the second quarter. Revenue jumped 53% year-over-year to $39.7 million, handily beating the $33.9 million consensus, driven by MIPLYFFA sales and expanded access program reimbursements. The company is now debt-free after repaying its $63.1 million term loan in March, and its cash and investments stand at $260.2 million — a fortress balance sheet that removes near-term financing risk. A setback came with the negative CHMP opinion on the European marketing application for arimoclomol, though a re-examination has been requested. Meanwhile, the celiprolol Phase 3 trial continues to enroll, with 66 participants as of quarter-end. This report confirms Zevra's transition to a self-funding commercial-stage rare disease company with ample runway.
At the time of this filing, ZVRA was trading at $10.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $622.5M. The 52-week trading range was $7.16 to $15.04. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.